Related Experiment Video

Updated: Jul 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic HSV-1 for the treatment of brain tumours

James M Markert1, Jacqueline N Parker, Donald J Buchsbaum

  • 1Division of Neurosurgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294-3410, USA. markert@uab.edu

Herpes : the Journal of the IHMF
|December 7, 2006
PubMed

Insights

Oncolytic virus therapy using Herpes simplex virus type 1 shows promise for malignant glioma treatment. This review explores clinical trials and future directions for this innovative approach to brain tumors.

Area of Science:

  • Neuro-oncology
  • Virology
  • Cancer Therapy

Background:

  • Malignant glioma, a common brain tumor, has a poor prognosis despite standard treatments.
  • Oncolytic viral therapy presents a novel treatment strategy for brain tumors.
  • Herpes simplex virus type 1 is a leading candidate for oncolytic virotherapy in neuro-oncology.

Purpose of the Study:

  • To review the background and development of oncolytic viral therapy for malignant glioma.
  • To discuss ongoing and completed clinical trials involving Herpes simplex virus type 1.
  • To explore future directions for oncolytic virotherapy in treating brain tumors.

Main Methods:

  • Literature review of oncolytic viral therapy research.
  • Analysis of clinical trial data for Herpes simplex virus type 1 in malignant glioma.
  • Discussion of therapeutic strategies and future research avenues.

Main Results:

  • Herpes simplex virus type 1-based oncolytic virotherapy is being investigated in multiple clinical trials for malignant glioma.
  • Conditional replication of Herpes simplex virus type 1 offers a targeted approach to cancer treatment.
  • The review synthesizes current evidence and identifies potential advancements.

Conclusions:

  • Oncolytic viral therapy, particularly with Herpes simplex virus type 1, represents a promising frontier in malignant glioma treatment.
  • Further clinical trials are essential to optimize efficacy and safety.
  • Future research should focus on enhancing viral delivery and therapeutic outcomes for brain tumors.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...